Arvind Dasari

Arvind Dasari is a Senior Professor at The University of Texas MD Anderson Cancer Center, specializing in gastrointestinal oncology, colorectal cancer, and radiation oncology. His research focuses on minimal residual disease (MRD) detection, immunotherapy combinations for mismatch repair-proficient rectal cancer, and functional liver imaging for reirradiation in liver malignancies. He has led phase 1b/2 trials evaluating novel agents such as NG-350A and TAS-102, and his recent work includes propensity-matched analyses of immunotherapy outcomes and benefit/risk assessments of fruquintinib in metastatic colorectal cancer. His contributions span clinical trial design, translational pharmacology, and molecular profiling of neuroendocrine tumors.